6925 Guion Road
Indianapolis, IN 46268
T: (317) 347-2800
Website: www.exeleadbiopharma.com


Exelead is a CDMO dedicated to the development and commercialization of therapeutics to treat life-threatening diseases. Exelead’s core technologies focus on the manufacture of sterile drug products specializing in liposomal and PEGylation formulation technologies. Exelead has development capabilities that can be utilized to improve drug delivery and drug product characterization. The Indianapolis, Indiana manufacturing facility produces proprietary parenteral pharmaceuticals for oncology and enzyme replacement treatment, as well as for the treatment of numerous infectious diseases.

Our staff is a balance of: chemists, chemical engineers, microbiologists, and pharmaceutical manufacturing experts. Senior Exelead management is a mix of seasoned executives from the pharmaceutical and biotechnology industries. Exelead is a wholly owned subsidiary of Essetifin S.p.A. (Rome, Italy) and is led by John Rigg, Vice President and General Manager.

Exelead manufactures drug products that are distributed globally and offers solutions at every phase of the drug development process (Pre-Clinical, Phase I/II/III, and Commercial). At Exelead, our mission centers not just on what we do, but whom we serve. Exelead offers rare dedication to the customer who needs a partner – not just a CMO/CDMO.


End-to-End Solution

– Method Development & Transfer

– Process Development and Optimization

– Technical Transfer

– Clinical Manufacturing

– Process Scale Up

– Commercial Manufacturing

– Project Management and CMC Support

Flexible Production

– Liposomal Formulation

– PEGylation

– Aseptic Fill

– Automated Inspection

– Packaging

– Quality Control

– Sterility Assurance

– Quality Assurance

– Supply Chain